PTGS2 and neoplasm: RIPK3 deficiency activates the NF-κB signaling pathway and upregulates the expression of the downstream signaling molecules COX-2 and PGE2, which aggravates the immunosuppressive activity of MDSCs and accelerates tumor growth.